Endocrine Gland Neoplasms  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
NCT01374906 / 2009-011128-70: Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Completed
3
150
Japan, US, Canada, Europe, RoW
pasireotide LAR, SOM230, SOM230 LAR 30 mg, SOM230 LAR 10 mg
Novartis Pharmaceuticals
Cushing's Disease
12/16
12/16

Download Options